CGC Stock Overview
Engages in the production, distribution, and sale of cannabis and hemp-based products for recreational and medical purposes primarily in the United States, Canada, Germany, and internationally.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 2/6 |
| Dividends | 0/6 |
Canopy Growth Corporation Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CA$7.30 |
| 52 Week High | CA$19.20 |
| 52 Week Low | CA$2.76 |
| Beta | 1.77 |
| 11 Month Change | 10.11% |
| 3 Month Change | -18.07% |
| 1 Year Change | 53.85% |
| 33 Year Change | -96.14% |
| 5 Year Change | -97.77% |
| Change since IPO | -77.88% |
Recent News & Updates
Recent updates
Canopy Growth: Cannabis Rally Loses Steam On Long-Term Uncertainty (Hold)
Jun 17Canopy Growth: Another Ugly Cannabis Report
Jun 03Canopy Growth Set For U.S. Cannabis Markets
Apr 26Canopy Growth Is Climbing, But It Won't Last
Mar 22Canopy Growth: Reiterate Strong Sell, Dilutive Offering Likely First Of Many To Come
Feb 06Canopy Growth: Further Implosion Is Now A Matter Of When Not If
Jan 29Avoid Canopy Growth After Failed Equity Sale
Jan 14Canopy Growth (Nasdaq:CGC): Further Dilution Seems Inevitable
Oct 13
Canopy Growth: Getting High
Oct 07Quick Takes: Tesla, Twitter, Carvana & More
Oct 06
Canopy Growth to sell Canadian retail operations, including Tokyo Smoke stores
Sep 27Canopy Growth: BioSteel Sizzles, Everything Else Fizzles
Aug 30What Is Canopy Growth's Stock Outlook After Earnings Miss?
Aug 23Canopy Growth leads cannabis rally as Senator backs compromise legislation
Aug 08Canopy gains 12% to lead Canadian cannabis rally as former Aphria legal chief joins
Aug 02Canopy Growth: Constellation's Investment Goes Up In Smoke
Jul 18Canopy Growth: Bankruptcy Risks Are Growing Like A Weed
Jun 28Canopy Growth: Still Not At Rock Bottom
May 27Can Canopy Growth's Stock Price Recover To $10?
May 04Shareholder Returns
| CGC | US Pharmaceuticals | US Market | |
|---|---|---|---|
| 7D | 2.4% | 0.004% | -2.4% |
| 1Y | 53.8% | 18.8% | 17.5% |
Return vs Industry: CGC exceeded the US Pharmaceuticals industry which returned 18.8% over the past year.
Return vs Market: CGC exceeded the US Market which returned 17.5% over the past year.
Price Volatility
| CGC volatility | |
|---|---|
| CGC Average Weekly Movement | 26.2% |
| Pharmaceuticals Industry Average Movement | 9.9% |
| Market Average Movement | 6.0% |
| 10% most volatile stocks in US Market | 14.9% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: CGC's share price has been volatile over the past 3 months.
Volatility Over Time: CGC's weekly volatility (26%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2009 | 1,029 | David Klein | www.canopygrowth.com |
Canopy Growth Corporation, together with its subsidiaries, engages in the production, distribution, and sale of cannabis and hemp-based products for recreational and medical purposes primarily in the United States, Canada, Germany, and internationally. It operates through Canada Cannabis, International Markets Cannabis, and Storz & Bickel segments. The company offers dried flower, pre-rolled joints, oils, softgel capsules, infused beverages, edibles comprising gummies, and topical formats, as well as vaporizer devices.
Canopy Growth Corporation Fundamentals Summary
| CGC fundamental statistics | |
|---|---|
| Market cap | US$580.24m |
| Earnings (TTM) | -US$349.64m |
| Revenue (TTM) | US$214.80m |
2.7x
P/S Ratio-1.7x
P/E RatioIs CGC overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| CGC income statement (TTM) | |
|---|---|
| Revenue | CA$297.15m |
| Cost of Revenue | CA$217.25m |
| Gross Profit | CA$79.90m |
| Other Expenses | CA$563.58m |
| Earnings | -CA$483.68m |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
Aug 09, 2024
| Earnings per share (EPS) | -5.97 |
| Gross Margin | 26.89% |
| Net Profit Margin | -162.78% |
| Debt/Equity Ratio | 119.3% |
How did CGC perform over the long term?
See historical performance and comparison